Why Am I Not Losing Weight on Tirzepatide? A Physician's Guide

If you are not losing weight on tirzepatide, the cause is far more often the timeline, the measurement or normal metabolic adaptation than a medication that has stopped working. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and nothing about its mechanism switches off after a few months. What changes is the body it is acting on, and what the bathroom scale is able to show you about that.

Here is the full list of reasons a stall happens, and who is responsible for sorting each one out. The right-hand column is the part most articles leave out.

Read that table once more and notice that exactly one row is yours to act on alone, and it is the measuring one. Every row that touches the drug belongs to the physician who prescribed it. That boundary is the whole argument of this article.

Protocol MD sells compounded tirzepatide, so we have a commercial interest in how you read this page. We have written it to talk you out of the single most common and most dangerous response to a stall, which is quietly taking more.

The most useful thing to know about a tirzepatide plateau is that the published trials are plateaus with extra steps. Weight loss on tirzepatide is front-loaded, and the curve flattens long before the trial ends.

SURMOUNT-1 randomly assigned 2,539 adults with obesity, or with overweight plus a weight-related complication and without diabetes, to tirzepatide or placebo for 72 weeks. That is sixteen and a half months, and it included a 20-week dose-escalation period at the start. Mean weight change at week 72 was -15.0% at the 5 mg dose the trial used, -19.5% at 10 mg and -20.9% at 15 mg, against -3.1% with placebo (Jastreboff et al., 2022).

SURMOUNT-4 is the trial that actually answers the plateau question, because it looked at what happens after the easy weight is gone. Participants took tirzepatide openly for a 36-week lead-in and lost a mean of 20.9%. They were then randomized either to keep taking it or to switch to placebo. Over the next 52 weeks, the people who continued tirzepatide lost a further 5.5%, while the people switched to placebo regained 14.0% (Aronne et al., 2024).

Those are averages from randomized trials of brand-name tirzepatide, reported between groups. They describe what happened to populations over fixed periods. They are not a forecast for any individual, and they are not a schedule your own weight should follow.

Look at the shape rather than the numbers. In the first nine months, the average participant lost about a fifth of their body weight. In the following twelve months, on the same drug at the same tolerated dose, they lost about a twentieth more. That is roughly a fivefold drop in the rate of loss, in people who were still responding, still supervised and still taking the medication.

A quiet scale at nine or twelve months is consistent with the flat part of that published curve rather than with a medication that has stopped working. Which of the two it is in your case is a question for your prescriber.

There is a real answer to this, and it is more reassuring than the internet suggests. In SURMOUNT-1, the share of participants who achieved a weight reduction of at least 5% was 85% at 5 mg, 89% at 10 mg and 91% at 15 mg, compared with 35% on placebo (Jastreboff et al., 2022).

Turn those numbers over. Between about 9% and 15% of trial participants did not reach a 5% reduction, depending on the dose group. So genuine low response to tirzepatide exists, it is uncommon, and it was measured at the end of 72 weeks of supervised treatment.

That last clause is the one that matters to you. The trial defined non-response after a year and a half. It did not define it at week 6, or week 12, or during the escalation period when most people have not yet reached their eventual dose. A flat scale early in a course is not evidence that you are in the 9% to 15%, because the trial would not have called it that either.

Non-response is also a conclusion a physician reaches by exclusion, after reviewing adherence, storage, concurrent medications, thyroid function and the other items further down this page. It is the last explanation, not the first one.

Body weight is not body fat. It is body fat plus muscle plus bone plus the contents of your gut plus several liters of water that move around on their own schedule. Fat loss happens slowly and steadily. The other components move fast enough to drown it out for weeks.

Four things routinely hide real fat loss on tirzepatide:

• Glycogen and the water bound to it. Every gram of stored carbohydrate holds roughly three grams of water. A few higher-carbohydrate days refill that store and the scale rises, with no fat gained at all.
• Sodium and hydration. A salty meal, a long flight, a hot week or a new medication can shift fluid balance by several pounds inside a day.
• Slowed gut transit. Tirzepatide delays gastric emptying, which is part of how it reduces appetite. Constipation is a common consequence, and stool mass is weight that sits on the scale without being fat.
• The menstrual cycle. Cyclical fluid retention regularly masks two weeks of genuine fat loss, then disappears overnight and looks like a sudden result.

Losing inches but not pounds on tirzepatide

This is the single most common version of a false plateau, and it has a straightforward explanation. If your waist measurement is falling and your clothes are looser while the scale sits still, fat is leaving and something else is holding its place.

What it is usually not is new muscle. Lean mass generally falls alongside fat during substantial weight loss, and across trials of GLP-1-based therapies the lean-mass share of total weight lost has ranged from about 15% or less up to 40% to 60%, depending on the population and the imaging method used (Neeland et al., 2024). That review also makes a point worth keeping: lean mass as measured includes organs, bone and fluid, not only muscle, which is exactly why body-composition readings wobble.

The practical move is to stop relying on a single number. Weigh at the same time of day under the same conditions and read the weekly average rather than any one morning. Take a waist measurement. Take photographs. Notice whether appetite and food noise are still suppressed, because that tells you the medication is engaged even when the scale is not cooperating.

When the scale genuinely stops for several weeks and the measurement explanations have been ruled out, the mechanism is almost always metabolic adaptation. This is normal physiology defending a body weight it has already learned, and it is not a sign that you did something wrong.

The part people get backwards is which half of the equation does the damage. Most articles blame a slowing metabolism. The better data says appetite is the larger force. Using a validated method applied to a 52-week placebo-controlled trial in which participants lost weight without being aware of the energy deficit, researchers calculated that weight loss drives a proportional rise in appetite of roughly 100 kcal per day for every kilogram of weight lost, an effect more than threefold larger than the matching adaptation in energy expenditure (Polidori et al., 2016).

That study was conducted in patients treated with a sodium-glucose co-transporter inhibitor, not a GLP-1 medication. It describes the appetite feedback that follows weight loss in general, whatever caused the weight loss. It is cited here to explain why plateaus happen, not as a tirzepatide result.

The direction matters far more than any single number, and the coefficient above was modeled over small losses rather than large ones, so do not multiply it out. What it establishes is that the more weight you lose, the harder appetite pushes back. Tirzepatide is pushing back against that pressure, and a fixed amount of drug pushing against a steadily growing force will eventually reach a standoff. The standoff is the plateau. It is also, quietly, the medication working, because without it the balance would have tipped the other way months ago. SURMOUNT-4 is the direct evidence of that: withdrawal produced a 14.0% regain.

The counterweight with the best evidence behind it is physical activity. A review of weight-loss maintenance concluded that few people manage to re-establish energy balance at a reduced body weight through food restriction alone, without a permanent increase in physical activity (Melby et al., 2019). Activity is also the one lever on this page that does not require a prescription, provided your physician has cleared you for it.

Tirzepatide reduces appetite. It does not choose what you eat, and after several months of suppressed hunger the fundamentals drift without anyone noticing. Four of them account for most of it.

• Protein falls away. Appetite suppression hits protein hardest, because protein-rich meals are the ones that take effort to prepare and chew. Protein is also what protects lean mass during weight loss, which makes it the first thing to check.
• Liquid calories creep back. Coffee drinks, juice and smoothies bypass the fullness signaling that tirzepatide amplifies, because the stomach distension that drives that signal barely happens.
• Alcohol does three jobs at once. It carries calories, it suppresses fat oxidation while the body deals with it, and it reliably degrades the sleep that follows.
• Resistance training disappears. Training preserves lean mass during weight loss, and lean mass is a meaningful share of resting energy expenditure. Losing it lowers the floor you are trying to stay under.

Sleep belongs on the list too. Short sleep raises appetite-signaling pressure and makes food decisions worse the following day, which stacks directly on top of the adaptation described above.

None of this is a secret, and none of it is where most stalls start. It is simply the set of things that have usually slipped by month nine, because nobody keeps anything perfectly for nine months.

Some stalls are not about tirzepatide at all. They are about something else in your chart that your prescriber may not yet know about, which is why a plateau is a reason to be reviewed rather than a reason to push the dose.

Conditions that commonly complicate weight loss include untreated hypothyroidism, polycystic ovary syndrome, obstructive sleep apnea, poorly controlled type 2 diabetes and, uncommonly, excess cortisol. Several of these are identified from a blood draw and a conversation.

Medication classes associated with weight gain or with resistance to weight loss include some antidepressants, several antipsychotics, corticosteroids, insulin and sulfonylureas, certain antiepileptics, some beta blockers and some hormonal contraceptives. None of these means you cannot lose weight, and none of them is a reason to stop a medication you were prescribed for another condition.

What it means in practice is simpler than it sounds: give your prescribing physician the complete list, including anything you take occasionally and anything you buy without a prescription. A plateau with an unexamined medication list is a plateau nobody can explain.

This is a different question from the one above it, and almost nobody writing about plateaus separates the two. If your tirzepatide comes from a compounding pharmacy in a multi-dose vial rather than from a manufactured pen, there are three uncertainties layered on top of all the normal reasons a scale stalls.

Compounded tirzepatide is not FDA-approved. The FDA's own wording is that compounded drugs do not undergo the agency's review for safety, effectiveness or quality before they are marketed, and that they should only be used for patients whose medical needs cannot be met by an FDA-approved drug (FDA, content current as of October 1, 2026). Nobody was studying a compounded preparation in SURMOUNT-1 or SURMOUNT-4, and the results of those trials belong to the product that was tested in them.

• Strength is not independently verified. With an approved product, the amount in the device has been reviewed by the FDA. With a compounded preparation it has not, which means a question like whether your vial is weaker than it should be cannot be answered by you at home, and cannot honestly be answered by a marketing page either. It is a question for the prescriber and the dispensing pharmacy, who can produce the pharmacy's documentation.
• Concentration varies between pharmacies. Compounded vials are not standardized, so the volume that delivers a given amount of drug is specific to the vial in your refrigerator. This is the origin of the units-versus-milligrams confusion that circulates in patient groups, and it is why advice copied from a stranger with a different vial is not merely unhelpful but unsafe. The FDA has noted adverse-event reports that may be related to dosing errors with compounded GLP-1 products.
• Handling matters more. A multi-dose vial is drawn up by the patient rather than delivered by a manufactured device, which puts storage, temperature and technique inside the variables. If any of those have slipped, the pharmacy that dispensed the vial is the right place to ask.

The honest summary is that a compounded preparation adds unknowns a brand-name product does not have, and that the correct response to those unknowns is a conversation with your prescriber and your pharmacy rather than a change you make yourself. Our guide to whether Zepbound is the same as tirzepatide sets out the regulatory differences in full.

Zepbound is tirzepatide. It is Eli Lilly's FDA-approved brand of the same molecule, approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity, and Mounjaro is the same molecule approved for type 2 diabetes. Every physiological explanation on this page applies to it unchanged, because the physiology belongs to the drug rather than to the label on the box.

So if you are not losing weight on Zepbound, start in the same place: the timeline, the scale, appetite adaptation, the fundamentals, then your medication list. A Zepbound plateau at month nine and a compounded tirzepatide plateau at month nine have the same differential.

Two things are genuinely different with the brand product, and both work in its favor. The strength in the pen is manufactured and consistent, which removes the strength and concentration uncertainties described above. And Zepbound is the product the SURMOUNT trials actually studied, so the figures quoted on this page describe it directly.

The practical difference is usually administrative rather than clinical. Gaps caused by insurance prior authorization, a lapsed savings program or a pharmacy supply interruption produce missed weeks, and missed weeks show up on the scale several weeks later. If your stall followed a gap in supply, bring the dates to your prescriber, because that is a different conversation from a plateau.

If you are on semaglutide rather than tirzepatide, the physiology overlaps but the timeline and the trial figures are different ones; we cover that query separately in why the scale stalls on semaglutide.

Here is the part of the article that most competing pages replace with a section headed you may need a higher dose. We will not, because a dose increase you make yourself is unsupervised prescribing, and it is the step this article exists to talk you out of.

Dose is a legitimate and frequent part of the answer. It is also a decision that belongs entirely to the physician who prescribed the medication, made against your labs, your history, your tolerance and the other medications you take. A prescriber reviewing a stall typically works through:

• How long you have actually been treated, counting from the start rather than from the current dose, and where that sits on the curve described above.
• Adherence and continuity, including missed weeks, gaps in supply and anything that interrupted treatment.
• Your current dose and your tolerance of it, which together determine whether an adjustment is appropriate and when.
• Storage and handling, especially for a compounded vial, and the pharmacy's documentation for it.
• Labs and conditions that bear on weight, such as thyroid function and glucose control.
• Your full medication list, looking for the weight-promoting classes above.
• What the trend actually shows across weeks of data rather than any single weigh-in, alongside waist measurements.
• Whether tirzepatide is still the right choice for you, which is a real option and an uncommon one.

What should not happen while you wait for that appointment: taking a larger amount from the vial, taking an extra dose, changing which day you dose, drawing from someone else's prescription, or acting on a dosing chart from a patient group. If the scale has not moved for several weeks, message your prescriber. That is the entire action item.

Protocol MD sells compounded tirzepatide and compounded semaglutide, so we profit when patients stay in treatment and we have a commercial interest in this topic. State it plainly and read the rest with it in mind. We do not sell Zepbound or Mounjaro.

The Protocol MD tirzepatide protocol has three steps: an online intake that screens for the contraindications above, a review by a US-licensed physician who decides whether a prescription is appropriate, and dispensing by a licensed 503A compounding pharmacy only if the physician approves. Protocol MD serves all 50 states. Your card is held at checkout and charged only after a physician approves your prescription.

When a Protocol MD patient stalls, the response is a physician review rather than an automatic escalation. If labs are part of that review, you order the lab, have blood drawn at a Labcorp or Quest location, and your results are uploaded to your patient portal as a results dashboard with feedback on what they show.

If you are on a GLP-1 from somewhere else and the scale has stopped, the most useful thing we can tell you is to take it to the physician who prescribed it. If you want a physician to look at your situation from the start, that is where it begins.

Why are you not losing weight on tirzepatide? Most of the time because the curve flattens by design after the first several months, because the scale is reporting fluid and gut contents alongside fat, and because appetite rises in proportion to the weight you have already lost. Low response is real, and 9% to 15% of SURMOUNT-1 participants did not reach a 5% reduction after 72 weeks of supervised treatment, depending on the dose group, but it is the explanation a physician reaches last. The move is to measure differently, hold the fundamentals, and bring a stall that lasts several weeks to your prescribing physician.

A plateau is information about your physiology, not a verdict on your effort, and the next step belongs to the physician who prescribed the medication.